Episode 308: 307. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES)

Kityo C et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): Week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis 2024 May 28; [e-pub]. (https://doi.org/10.1016/S1473-3099(24)00289-5)307